Innoviva Stock

$19.65

7.14% yesterday

Nasdaq, Aug 11, 10:16 pm CET

ISIN

US45781M1018

Symbol

INVA

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Innoviva Stock price

$19.65

+6.06 44.59% 5Y

Nasdaq, Closing price Mon, Aug 11 2025

+1.31 7.14%

ISIN

US45781M1018

Symbol

INVA

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.2b

Enterprise Value

$1.2b

Net debt

$2.0m

Cash

$446.9m

Shares outstanding

62.8m

Valuation (TTM | estimate)

P/E

negative | 26.8

P/S

3.3 | 3.1

EV/Sales

3.4 | 3.1

EV/FCF

6.2

P/B

1.9

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$369.8m | $374.2m

EBITDA

$208.4m | $160.0m

EBIT

$182.5m | $163.4m

Net Income

$-59.7m | $42.9m

Free Cash Flow

$200.3m

Growth (TTM | estimate)

Revenue

18.7% | 4.3%

EBITDA

55.3% | -17.0%

EBIT

66.3% | -2.1%

Net Income

-132.9% | 83.4%

Free Cash Flow

31.8%

Financial Health

Equity Ratio

53.1%

Return on Equity

3.4%

ROCE

17.9%

ROIC

30.0%

Debt/Equity

0.7

EPS

$-1.0

FCF per Share

$3.2

Short interest

21.9%

Employees

127

Rev per Employee

$2.8m

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

Innoviva Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Innoviva forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Innoviva forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	370 370	19% 19% 100%
- Direct Costs	34 34	20% 20% 9%
Gross Profit	335 335	25% 25% 91%
- Selling and Administrative Expenses	113 113	4% 4% 30%
- Research and Development Expense	14 14	44% 44% 4%
EBITDA	208 208	55% 55% 56%
- Depreciation and Amortization	26 26	6% 6% 7%
EBIT (Operating Income) EBIT	182 182	66% 66% 49%
Net Profit	-60 -60	133% 133% -16%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Innoviva Stock News

Neutral

The Motley Fool

●

5 days ago

Innoviva (INVA) Q2 Sales Jump 64%

Innoviva (INVA -1.03%), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share (GAAP) of $0.77 on $100.3 million in revenue.

Neutral

Business Wire

●

5 days ago

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June ...

Neutral

Business Wire

●

2 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, ...

More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office	United States
CEO	Mr. Raifeld
Employees	127
Founded	1996
Website	www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now